CASSAVA SCIENCES (SAVA) Company Report

Cassava Sciences announced the publication of detailed results from its Phase 3 RETHINK-ALZ and REFOCUS-ALZ clinical trials for simufilam in Alzheimer’s disease in the Journal of Prevention of Alzheimer’s Disease.
The studies did not meet their pre-specified co-primary, secondary, or exploratory biomarker endpoints, leading the company to discontinue development of, and plan no further investment in, the Alzheimer’s disease program.
Despite the lack of efficacy, the paper confirmed simufilam’s favorable safety profile in these studies.
The company is now focusing on developing simufilam for Tuberous Sclerosis Complex (TSC)-related epilepsy and plans to initiate a proof-of-concept study.

Jan 13, 2026, 1:00 PM

Cassava Sciences Settles Securities Class Action Lawsuit

SAVA

Legal Proceedings

Accounting Changes

Cassava Sciences, Inc. (SAVA) has entered into a binding settlement agreement to resolve a consolidated securities class action lawsuit.
The company will pay $31.25 million to the plaintiffs, with the amount expected to be placed into escrow in January 2026.
This settlement provides full and complete releases for the company and certain individuals, without admitting fault or wrongdoing.
Cassava Sciences had reserved a loss contingency of $31.25 million in the second quarter of 2025 related to this action.

Dec 23, 2025, 1:46 PM

Cassava Sciences Settles Securities Class Action Litigation

SAVA

Legal Proceedings

Cassava Sciences (SAVA) has reached a definitive agreement to resolve a consolidated securities class action litigation.
The company will pay $31.25 million to settle all claims, covering the period between September 14, 2020, and October 12, 2023.
A loss contingency of $31.25 million was fully reserved in the second quarter of 2025 for this settlement.
The settlement is not an admission of fault or wrongdoing by Cassava Sciences.
This resolution allows the company to focus resources on the continued development of simufilam for TSC-related epilepsy.

Dec 23, 2025, 1:00 PM

Cassava Sciences Reports Q3 2025 Financials and Business Update

SAVA

Earnings

Guidance Update

New Projects/Investments

Cassava Sciences reported a net loss of $10.8 million, or $0.22 per share, for the third quarter ended September 30, 2025, compared to a net loss of $27.9 million, or $0.58 per share, for the same period in 2024.
The company held $106.1 million in cash and cash equivalents as of September 30, 2025, with no debt, and expects cash at year-end 2025 to be in the range of $92 million to $96 million, which is anticipated to support operations into 2027.
Simufilam is advancing as a potential treatment for TSC-related epilepsy, with a clinical study expected to begin in H1 2026.
Dawn C. Bir was appointed as an Independent Director in October 2025, and Joseph Hulihan, MD, MSHP, was appointed Chief Medical Officer in August 2025.